Literature DB >> 17728365

Peripheral vascular disease in systemic lupus erythematosus.

S P Bhatt1, R Handa, G S Gulati, S Sharma, R M Pandey, P Aggarwal, L Ramakrishnan, S Shankar.   

Abstract

With increasing longevity of lupus patients, peripheral vascular disease (PVD) has become an important cause of morbidity. With no systematic study of PVD in systemic lupus erythematosus (SLE), this study was undertaken to define the frequency and spectrum of PVD in SLE and factors affecting such an occurrence. All medium-sized peripheral arteries of bilateral upper and lower extremities were studied in 50 SLE patients using Doppler ultrasonography. PVD was defined clinically as one or more of intermittent claudication, absent/unequal pulses, gangrene or ischemic ulcers and sub-clinically as asymptomatic patients with Doppler abnormalities, with > or =50% reduction in diameter considered hemodynamically significant. Mean (SD) age of the patients was 31.6 (10.1) years. Forty-one percent were hypertensive. Dyslipidemia was found in 62%. Fifteen (30%) had Raynaud's phenomenon. Fourteen (28%) patients had PVD, of whom three had positive markers for antiphospholipid antibody (aPL) and six were asymptomatic. Ischemic ulcers were seen in eight (16%), gangrene in three (6%), femoral artery plaques in two (4%), stenosis in four (8%) and intermittent claudication in none. Dyslipidemia was found to independently affect occurrence of PVD (OR = 5.37, [95% CI 1.05-27.5], P = 0.05). The causes of PVD overlap significantly and further studies are needed to ascertain the relative contribution of each.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728365     DOI: 10.1177/0961203307081123

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX).

Authors:  P I Burgos; L M Vilá; J D Reveille; G S Alarcón
Journal:  Lupus       Date:  2009-10-22       Impact factor: 2.911

2.  Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian state.

Authors:  Elise Danielle McVeigh; Amna Batool; Arnold Stromberg; Ahmed Abdel-Latif; Nayef Mohammed Kazzaz
Journal:  Lupus Sci Med       Date:  2021-05

Review 3.  Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.

Authors:  Vítor Teixeira; Lai-Shan Tam
Journal:  Front Med (Lausanne)       Date:  2018-01-29

4.  Categorisation of foot complaints in systemic lupus erythematosus (SLE) from a New Zealand cohort.

Authors:  Simon J Otter; Maheswaran Rohan; Kevin A Davies; Sunil Kumar; Peter Gow; Nicola Dalbeth; Michael Corkill; Sam Panthakalam; Keith Rome
Journal:  J Foot Ankle Res       Date:  2017-07-26       Impact factor: 2.303

Review 5.  Management of cardiovascular disease in patients with systemic lupus erythematosus.

Authors:  Paramarjan Piranavan; Andras Perl
Journal:  Expert Opin Pharmacother       Date:  2020-06-08       Impact factor: 3.889

6.  Patterns of foot complaints in systemic lupus erythematosus: a cross sectional survey.

Authors:  Simon J Otter; Sunil Kumar; Peter Gow; Nicola Dalbeth; Michael Corkill; Maheswaran Rohan; Kevin A Davies; Sam Pankathelam; Keith Rome
Journal:  J Foot Ankle Res       Date:  2016-03-22       Impact factor: 2.303

7.  Phalangeal Microgeodic Syndrome in a Patient with Systemic Lupus Erythematosus.

Authors:  Shota Kurushima; Yoshiro Horai; Ayuko Takatani; Ayako Nishino; Shin-Ya Kawashiri; Kunihiro Ichinose; Hideki Nakamura; Atsushi Kawakami
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

8.  Interleukin-17 Reduces βENaC via MAPK Signaling in Vascular Smooth Muscle Cells.

Authors:  Jeremy W Duncan; Joey P Granger; Michael J Ryan; Heather A Drummond
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

9.  Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study.

Authors:  Ya-Wen Chuang; Mei-Ching Yu; Cheng-Li Lin; Tung-Min Yu; Kuo-Hsiung Shu; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.